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ABSTRACT 22 
Shortened leukocyte and placental telomeres associated with gestational diabetes mellitus 23 
(GDM) suggest this exposure triggers telomere attrition contributing to adverse outcomes. We 24 
applied high resolution Single Telomere Length Analysis (STELA) to placenta from GDM 25 
pregnancies with different treatment pathways to determine their effectiveness at preventing 26 
telomere attrition. Differences in telomere length between control (N = 69), GDM lifestyle 27 
intervention (n = 14) and GDM treated with metformin and/or insulin (n = 17) was tested by 28 
Analysis of Covariance (ANCOVA) followed by group comparisons using Fisher’s least 29 
significant difference. For male placenta only, there were differences in mean telomere length 30 
(F(2,54)=4.98, P = 0.01) and percentage of telomeres under 5 kb (F(2,54)=4.65, P = 0.01). 31 
Telomeres were shorter in the GDM lifestyle intervention group compared to both controls (P 32 
= 0.02) and medically treated pregnancies (P = 0.003). There were more telomeres under 5 kb 33 
in the GDM lifestyle intervention group compared to the other two groups (P = 0.03 and P = 34 
0.004).  Although further work is necessary, we suggest that early adoption of targeted medical 35 
treatment of GDM pregnancies where the fetus is known to be male may be an effective 36 
strategy for ameliorating adverse outcomes for children. 37 
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Abbreviations 42 
FISH         Fluorescence in situ hybridization  43 
GDM         Gestational diabetes mellitus 44 
STELA      Single telomere length analysis 45 
T2DM        Type 2 diabetes mellitusTweeter  46 
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Introduction 47 
Gestational diabetes mellitus (GDM) can be defined as any degree of glucose intolerance with 48 
onset or first recognition during pregnancy [1]. One in seven births is affected by gestational 49 
diabetes (GDM) and these numbers are expected to increase in the years ahead, as reported by 50 
the International Diabetes Federation. During a normal pregnancy, the maternal system 51 
develops insulin resistance, increasing progressively towards term, to ensure nutrients are 52 
channelled to the developing foetus. GDM is thought to arise when peripheral insulin resistance 53 
exceeds an appropriate threshold, resulting in hyperglycaemia. The development of GDM 54 
involves both genetic and lifestyle factors, with overweight and obese women at highest risk 55 
[2]. While GDM can be controlled by diet or drugs, uncontrolled GDM increases the risk of 56 
delivering a large for gestational age baby (birth weight above the 90th percentile) and delivery 57 
by Caesarean section [3]. Women diagnosed with GDM are more likely to experience 58 
pregnancy related depression [4] and seven times more likely to develop type 2 diabetes 59 
mellitus (T2DM) later in life [5]. Their children are less likely to reach timely developmental 60 
milestones [6] and more likely to be overweight and with a six-fold increased risk of T2DM 61 
[7, 8]. Given the increasing prevalence of maternal obesity worldwide, understanding the 62 
consequences of GDM has even greater significance. 63 
 64 
A number of studies report that individuals with T2DM have shorter telomeres [9]. Telomeres, 65 
which consist of the repeated DNA sequence TTAGGG, acts as caps at the ends of 66 
chromosomes [10] to maintain genomic stability [11]. Telomeres shorten with progressive cell 67 
division, due to the inability of conventional DNA polymerase to complete the replication of 68 
chromosome ends. While the ribonucleoprotein enzyme telomerase adds telomere repeats to 69 
mitigate telomere erosion, the majority of somatic cells lack significant telomerase activity [12, 70 
13] consequently telomeres progressively shorten as cells divide and as individuals age. The 71 
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presence of shortened telomeres in T2DM patients suggests the possibility that diabetes 72 
contributes to telomere erosion. Conversely, individuals may start life with shorter than normal 73 
telomeres that then play a role in the disease progression of diabetes [14], contributing to 74 
impaired glucose management and insulin secretion [15]. The latter possibility is indicated by 75 
the observation that diabetes during pregnancy, is linked to shortened telomere length in blood 76 
leukocytes from exposed children [16, 17], although not all studies report such a link [18-20]. 77 
If individuals exposed in utero to GDM start life with shorter telomeres, this may explain why 78 
they are at higher risk of adverse outcomes such as T2DM later in life. However, fetal tissues 79 
are not easily accessible for measuring properties of DNA and there are considerable issues 80 
with the use of heterogeneous white blood cell samples [21]. In contrast, the placenta is a 81 
fetally-derived tissue exposed to the same environment as the foetus [22], in which telomere 82 
length can easily be determined. An association between GDM and shorter telomere length in 83 
the placenta has been reported using the fluorescence in situ hybridization (FISH) assay on 16 84 
samples [23]. In this study, shortened telomeres were defined by a weak signal intensity, and 85 
further analysis revealed significantly lower telomerase expression in these same samples [20]. 86 
Despite the clinical importance of GDM, few studies have examined placental telomeres in 87 
relation to GDM, and none have applied higher resolution assays.  88 
 89 
We recently applied Single Telomere Length Analysis (STELA) to placental telomere analysis 90 
[24]. STELA is a single-molecule PCR based telomere length analysis technology that 91 
determined the telomere length profiles from single chromosome ends [25]. This high-92 
resolution technique provides information on individual telomere length which can reveal 93 
additional information such as the remarkable heterogeneity present in term placenta [24]. In 94 
conjunction with University Hospital of Wales and Royal Gwent Hospital, we engaged in a 95 
study to investigate placental telomere from term pregnancies in Welsh women. From these 96 
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populations, we collected placenta from uncomplicated and GDM pregnancies making a note 97 
of their treatment pathways, and applied STELA. 98 
 99 
Materials and Methods 100 
Participant recruitment 101 
Study participants (N=100) were recruited and written informed consent was obtained prior to 102 
delivery at University Hospital Wales and Royal Gwent Hospital as described previously [26]. 103 
Ethical approval for the human study “Determining the expression levels of a set of imprinted 104 
genes in the term placenta from both normal and atypical pregnancies” was obtained via South 105 
East Wales Research Ethics Committee Panel B in 2010, REC number 10/WSE02/10. Sponsor: 106 
NHS – Cardiff and Vale ULHB. Ethical approval for the human study “The Grown in Wales 107 
Study: Developing a placentomic tool for characterising atypical pregnancies and predicting 108 
outcomes” was obtained via Wales Research Ethics Committee 2 2015, REC number 109 
15/WA/0004. Research was carried in accordance with the principles of the Declaration of 110 
Helsinki as revised in 2008. 111 
Placental biopsies  112 
Term placenta (37-42 weeks) were collected by trained research midwives within two hours of 113 
an elective caesarean section from singleton pregnancies. Unless otherwise stated, chorionic 114 
villous samples were taken 1 cm below the surface from the maternal side of the placenta at 5 115 
different sites midway between the cord insertion and the lateral edge. Samples were washed 116 
three times in phosphate buffered saline and stored in RNAlater at -80°C until needed.  117 
Subjects 118 
In Cardiff and Vale, high risk women (defined by a BMI over 30, prior history of gestational 119 
diabetes or macrosomic infant, family history of diabetes and Asian, African-Caribbean or 120 
Middle Eastern origins) are routinely offered glucose tolerance testing. Women with either a 121 
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fasting plasma glucose level of 5.6 mmol/l or above, or a 2-hour plasma glucose level of 7.8 122 
mmol/l or above, are initially offered dietary advice and recommended to undertake regular 123 
exercise with a common recommendation being at least 150 minutes (2 hours and 30 minutes) 124 
of moderate exercise, such as brisk walking or swimming, per week. If blood sugar levels 125 
remain elevated, women are prescribed medication which is usually metformin but can involve 126 
insulin injections for women who cannot take metformin or whose blood sugar is dangerously 127 
high. In this study 31 women with GDM were identified with a note being made of treatment 128 
pathways and 69 women were identified who had undergone GTT with no evidence of diabetes 129 
(Table 1). 130 
 131 
Table 1. Maternal, birth and metabolic characteristics in the control, lifestyle 132 
intervention and medication group.  133 
Mean (SD) or number (%) is shown. Note: due to missing values, some numbers do not add 134 
up to 100%. P values were assessed using one-way analysis of variance (ANOVA), Kruskal-135 
Wallis test or χ2.test.  136 
Study participants Lifestyle 
intervention 
group (GDM) 
N=14 
Medication 
group 
(GDM+M) 
N=17 
Control 
group 
 
N=69 
P 
VALUE 
Maternal characteristics     
 Ethnicity (White) 13(93%) 13(76%) 62(90%) 0.26 
 Parity 
 Primiparous 
 Multiparous 
 
3(21.4%) 
5(35.7%) 
 
 
0(0%) 
12(70.6%) 
 
7(10.1%) 
51(74%) 
0.42 
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 Maternal age 34(3.6) 32(3.9) 31(5.8) 0.23 
 Maternal BMI 31(7.8) 33(6.3) 31(6.3) 0.26 
 Weight gain 11.2(13) 10.8(5.5) 13.3(8.3) 0.65 
 Mode of delivery 
 Elective C-section 
 
14(100%) 17(100%) 69(100%) NA 
 Smoking 0(0%) 1(5.88%) 8(11.6%) 0.43 
 Socio-economic status 
 Lowest income 
 
0(0%) 2(11.8%) 
 
9(13%) 0.1 
Birth outcome 
 Birth weight (g) 
 
3734(503) 
 
3697(382) 
 
 
3734(562) 
 
0.96 
 Gestational age (weeks) 38(0.6) 38(0.6) 39(0.7) 0.034 
 Placental weight (g) 691(149.8) 709(119.1) 723(133.4) 0.69 
 Gender 
 Male 
 Female 
 
10(71.4%) 
  4(28.6%) 
 
10(58.8%) 
  7(41.2%) 
 
38(55.1%) 
31(44.9%) 
0.53 
Metabolic characteristics 
 Fasting plasma glucose 
(mmol/l) 
 
5.2(1.2) 
 
 
5.9(1.1) 
 
 
4.55(0.5) 
 
 
<0.0001 
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 2 hours glucose 
(mmol/l) 
8.1(2.6) 9.5(1.4) 5.46(1.3) <0.0001 
 137 
STELA (Single Telomere Length Analysis) 138 
STELA was performed as described previously [27]. Briefly, genomic DNA for each sample 139 
was amplified in multiple reactions (usually six reactions per sample) using telorette2, teltail 140 
and telomere specific primer XpYpE2. Amplified telomeric DNA fragments were then 141 
resolved by 0.5% agarose gel electrophoresis, detected by Southern hybridisation using a 142 
TTAGGG repeat probe α-33P dCTP labelled (Perkin Elmer) before visualisation using a 143 
Typhoon FLA 9500 phosphoimager (GE Healthcare Life Sciences). Telomere length 144 
distributions were determined using the ImageQuant software and descriptive statistics 145 
generated.  146 
Statistics 147 
All statistical analysis was performed using SPSS 23.0 for Windows. Data are expressed as 148 
means with standard deviation, or as numbers (%). Differences between groups were assessed 149 
using one-way analysis of variance (ANOVA) for characteristics that followed a normal 150 
distribution (maternal age, BMI, weight gain, birth weight and placental weight) and the 151 
Kruskal-Wallis test for characteristics that followed a non-normal distribution (gestational age 152 
in weeks, fasting glucose and 2 hours glucose). χ2 test was used for categorical data. 153 
Relationships between the main dependent variable and other variables was analysed by simple 154 
linear regression, or by Hierarchical regression allowing the entry of multiple independent 155 
variables if significant at P < 0.05. Differences in telomere length between the control group, 156 
the GDM lifestyle intervention group and the GDM mothers treated with metformin and/or 157 
insulin were tested by Analysis of Covariance (ANCOVA). ANCOVA was conducted to adjust 158 
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for maternal ethnicity and P ≤ 0.05 was considered statistically significant. This was followed 159 
by group comparisons using Fisher’s least significant difference (LSD) method.   160 
 10 
Results 161 
Maternal, birth and metabolic characteristics of the study participants 162 
GDM mothers (n = 31) and control mothers (n = 69) were predominantly White, consistent 163 
with the local population (Table 1). As ethnicity [28], maternal age [29] and obesity [30] are 164 
all risk factors for GDM, controls were matched for these characteristics. Other than fasting 165 
plasma glucose and 2 hours plasma glucose levels, only gestational age was significantly 166 
different between the groups (P = 0.034) with GDM mothers, on average, giving birth one 167 
week earlier than controls.  168 
Association between telomere length and potential confounders 169 
We have previously shown, using XpYp STELA, that telomere length and heterogeneity does 170 
not vary with fetal sex, mode of delivery or sampling site in a healthy pregnancy [24]. In this 171 
study, there was no significant relationship (P > 0.1) between placental telomere length and 172 
variables including maternal BMI, weight gain, socio-economic status, maternal age, 173 
gestational age, birth weight and smoking. However, within the control group (n = 69) there 174 
was a significant association between placental telomere length and maternal ethnicity (P = 175 
0.02), which has been previously described [31].  176 
Telomere length is associated with in utero exposure to poorly controlled hyperglycaemia 177 
in male placenta. 178 
The GDM group included 14 mothers who undertook dietary and exercise changes (lifestyle 179 
intervention group) and 17 mothers prescribed insulin and/or metformin (medication group; 180 
Table 1). Direct observation of the STELA telomere-length profiles identified GDM 181 
participants with markedly shortened placental telomeres, which were found to be exclusively 182 
from women who did not take medication for GDM (Fig 1).  183 
 184 
 185 
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Fig 1. Representative STELA comparing placental samples from control, GDM lifestyle 186 
intervention (labelled GDM) and GDM medication (labelled GDM+M) groups. Red 187 
dashed line across the STELA profiles indicate the mean. Each sample is analysed with six 188 
STELA reactions. Mean telomere lengths are presented below each sample (±SD).  189 
 190 
 191 
Telomeres in the lifestyle intervention group were, on average, 1 kb shorter than those in either 192 
the control or medication groups but this was not significant as assessed by ANCOVA 193 
(F(2,96)=1.66, P = 0.2) (Fig 2a). Similarly, there were 7% more telomeres below 5 kb in the 194 
lifestyle intervention group but again, without significance (Fig 2b). However, when samples 195 
where further separated by foetal sex, this revealed significant mean telomere length 196 
differences in male placenta between control, GDM lifestyle intervention and GDM medication 197 
groups by ANCOVA (F(2,54)=4.98, P = 0.01). Telomeres were shorter in the GDM lifestyle 198 
intervention group compared to both the control group (P = 0.02) and the GDM medication 199 
group (P = 0.003) (Fig 2c). Consistent with this observation, the percentage of telomeres under 200 
5 kb was about one-third higher in the GDM lifestyle intervention group compared to the 201 
control group (P = 0.03) and a greater than two-fold compared to the GDM medication group 202 
(P = 0.004) as assessed by ANCOVA (F(2,54)=4.65, P = 0.01) (Fig 2d). For the placenta from 203 
female infants, fewer samples were available and no significant differences in telomere length 204 
were identified between the three groups (Fig 2e and f).  205 
 206 
Fig 2. Telomere length differences in placenta from control, GDM and GDM+M groups. 207 
Comparison of mean telomere length between control, GDM and GDM+M groups 208 
(N=69+14+17) (a), in male placenta (N=38+10+10) (c), and in female placenta (N=31+4+7) 209 
(e). Differences in percentage of telomeres under 5kb between control, GDM and GDM+M 210 
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groups (N=69+14+17) (b), in male placenta (N=38+10+10) (d), and in female placenta 211 
(N=31+4+7) (f). Mean telomere length and percentage under 5kb is presented (±SD). 212 
ANCOVA test was used to assess statistical significant differences *p<0.05. 213 
  214 
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Discussion 215 
There is a growing concern that telomere shortening as a consequence of prenatal adversities 216 
such as GDM contributes to the increased occurrence of chronic diseases later in life such as 217 
T2DM [32]. In this study, we applied high-resolution telomere length analysis to examine 218 
placental telomeres and provide further support for the hypothesis that GDM may exacerbate 219 
telomere shortening. We further show that treatment of GDM mothers with metformin and/or 220 
insulin is not associated with telomere shortening suggesting that this treatment pathway 221 
protects against telomere erosion, an observation with potentially important clinical 222 
implications for longer term outcomes. 223 
Telomere length is inherited from the paternal and maternal gametes and consequently at 224 
fertilisation each chromosomal telomere starts the new generation at one of two possible 225 
lengths. The remarkable telomere heterogeneity we observe in the term placenta arises from an 226 
estimated 36 rounds of cell division during gestation [33] indicating a highly dynamic process 227 
of telomere maintenance in the placenta. This led us to hypothesise that placental telomeres 228 
might provide a sensitive tool for assaying prenatal adversity and, potentially, also measuring 229 
the effectiveness of intervention strategies, which we demonstrate here in relation to GDM. 230 
We have not shown, in this study, whether the shortened telomeres were inherited by the 231 
offspring. While some studies suggest that this is the case [16, 17], other studies find no such 232 
association [18-20]. This may be due to the technical challenges imposed by the use of 233 
leukocyte DNA. We show here that placental telomere measurements by STELA provides an 234 
alternative, sensitive and accurate tool to quantify exposure to GDM. 235 
In this study, we observed shortened telomeres in placenta from women whose GDM was 236 
managed only through exercise and diet. We anticipated was that women with more severe 237 
GDM, in the medication group, would have the shortest placental telomeres. However, the ten 238 
placenta from this group had telomeres in the normal range for a non-diabetic pregnancy. This 239 
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suggests treatment with metformin/insulin protects against telomere erosion. Metformin has 240 
already been proposed as a potential anti-aging drug after experiments in rodents indicated the 241 
drug alleviates age-related conditions such as inflammation, oxidative damage and cell 242 
senescence [34]. Metformin may function by promoting the upregulation of the telomere 243 
repeat-containing ribonucleic acid (TERRA) [35]. Alternatively, metformin may prevent 244 
accumulation of senescent (“old”) cells thus decreasing senescent cell abundance as a function 245 
of total cell number [36]. A third possibility is that metformin acts indirectly by dampening 246 
down the chronic inflammations associated with GDM [37]. Further work is required both to 247 
validate our original findings and to explore mechanisms in detail. 248 
Although we have very small numbers of girls from the GDM lifestyle intervention group, data 249 
from the four placenta analysed revealed similar profiles to the control and medically treated 250 
groups. This is potentially of interest as studies suggest a difference in the response of male 251 
and female offspring to diabetic pregnancies. For example, exposure to GDM is a risk factor 252 
for childhood overweight in boys, but not in girls [38] [39]. Telomere length in blood 253 
leukocytes has been reported to be reduced in girls exposed in utero to GDM but not boys [17]. 254 
It may be possible to reconcile these differences if women carrying a male foetus are more 255 
likely to take medication, which has been reported [40]. Further research is required. 256 
While the data from our study is exciting, there are limitations. Due to the smaller number of 257 
placental samples from girls, we cannot conclude the relationship between telomere length, 258 
GDM and medical treatment is restricted to boys. Secondly, while we have statistically 259 
controlled for a number of factors which may impact telomere length, questionnaire based 260 
studies are inherently subjective and there may be other factors independent of GDM and 261 
medical treatment influencing telomere length. As we studied term placenta in individual 262 
pregnancies, we do not know when the telomere changes took place and it is possible that the 263 
differences in telomere length were inherited. A further limitation is that STELA provides 264 
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information for only a subset of chromosomes. Previous works indicates that that telomere 265 
distributions are similar between sex chromosomes and autosomal chromosomes [41]. 266 
However, it will be important to validate our findings on XpY. 267 
  268 
In summary, we measured telomere length with respect to gestational diabetes diagnosis 269 
factoring in foetal sex and treatment pathways. Using STELA we were able to generate high-270 
resolution telomere length profiles from placental samples and we found that placental 271 
telomere shortening associated with GDM was prevented by maternal treatment with 272 
metformin and/or insulin. It will now be important to expand on these findings to understanding 273 
the underlying mechanism and long term consequence of different treatment pathways. 274 
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